Correlation between serum GLP-1,Aβ1-42,MCP-1 levels and cognitive dysfunction in patients with type 2 diabetes mellitus
Objective To investigate the correlation between serum levels of glucagon-like peptide-1 (GLP-1),amyloid beta 1-42(Aβ1-42),monocyte chemotactic protein-1(MCP-1)and cognitive dysfunction in patients with type 2 diabetes mellitus(T2DM). Methods The clinical data of 102 patients with T2DM ad-mitted to Nanjing Jiangning Hospital from February 2020 to February 2023 were retrospectively analyzed. The patients were then divided into two groups:a normal group(n=53)and a disabled group(n=49)based on their Montreal Cognitive Assessment Scale(MoCA)scores. Serum levels of GLP-1,Aβ1-42 and MCP-1 were compared between the two groups. The ROC curves were created to assess the predictive value of single and combined detection of these indicators for cognitive dysfunction in T2DM patients. Results The level of GLP-1 was higher in the normal group than in the disabled group,and the difference was statistically signifi-cant(t=6.738,P<0.05). The levels of serum Aβ1-42,MCP-1,FPG and HbA1c in the two groups were high-er in the cognitive dysfunction group than in the group with normal cognitive function ,and the differences were statistically significant(t=6.042,8.255,3.985,2.259,P<0.05). A correlation model was established, showing that the cognitive function of T2DM patients was positively correlated with GLP-1 level(r=0.486,P<0.05),and negatively correlated with Aβ1-42 and MCP-1 levels(r=-0.558,0.601,P<0.05). Multivariate logistic regression analysis revealed that GLP-1,Aβ1-42 and MCP-1 were independent influencing factors of cognitive dysfunction in T2DM patients(P<0.05). The ROC curve demonstrated that when GLP-1,Aβ1-42 and MCP-1 were combined,the AUC for predicting cognitive dysfunction in T2DM patients was 0.990,with a sensitivity of 0.910 and specificity of 0.952 ,which was better than that of single detection (P<0.05). Conclusion Serum MCP-1 levels were significantly increased in T2DM patients with cognitive impairment, while Aβ1-42 and GLP-1 levels were significantly decreased. The combined detection of these three indicators can provide an important reference for preventing cognitive impairment in T2DM patients.
Type 2 diabetes mellitusGlucagon-like peptide-1Amyloid beta 1-42Monocyte chemotactic protein-1Cognitive dysfunction
万方数据
维普
